Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

Nature communications·2026
Same author

Imaging the later-life white matter pathologies of repetitive head impacts: A novel pattern revealed through T2 FLAIR MRI.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Pontine pathology mediates common symptoms of blast-induced chronic mild traumatic brain injury.

Brain communications·2026
Same author

Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts.

Neurology·2026
Same author

Alterations in CSF Amyloid-β and Tau Biomarkers in Former College and Professional American Football Players: Findings from the DIAGNOSE CTE Research Project.

Journal of neurotrauma·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Mar 1, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

16.2K

An indicator cell assay for blood-based diagnostics.

Samuel A Danziger1,2, Leslie R Miller1, Karanbir Singh1

  • 1Institute for Systems Biology, Seattle, WA, United States of America.

Plos One
|June 9, 2017
PubMed
Summary
This summary is machine-generated.

The Indicator Cell Assay Platform (iCAP) uses specialized cells as biosensors for blood diagnostics. This novel platform shows promise in detecting pre-symptomatic diseases like ALS and early-stage Alzheimer's disease.

More Related Videos

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

16.2K
Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

14.0K
Real-time Cytotoxicity Assays in Human Whole Blood
08:27

Real-time Cytotoxicity Assays in Human Whole Blood

Published on: November 7, 2014

12.7K

Area of Science:

  • Biotechnology
  • Diagnostic Assays
  • Biomarker Discovery

Background:

  • Blood-based diagnostics are crucial for early disease detection.
  • Existing diagnostic tools face limitations in detecting pre-symptomatic or early-stage conditions.
  • The need for broadly applicable diagnostic platforms is significant.

Purpose of the Study:

  • To establish proof of principle for the Indicator Cell Assay Platform (iCAP).
  • To demonstrate iCAP's utility as a broadly applicable tool for blood-based diagnostics.
  • To validate iCAP's capability in detecting pre-symptomatic and early-stage neurodegenerative diseases.

Main Methods:

  • Utilized standardized indicator cells as biosensors exposed to patient serum in vitro.
  • Trained disease classifiers using differential response patterns of indicator cells.
  • Evaluated iCAP performance in murine models of ALS and Huntington's disease.
  • Assessed iCAP's accuracy in detecting early-stage Alzheimer's disease in human subjects.

Main Results:

  • Achieved 94% accuracy in detecting pre-symptomatic amyotrophic lateral sclerosis (ALS) in a murine model (p=3.81E-6).
  • Correctly identified Huntington's disease mouse models as non-ALS carriers.
  • Demonstrated 72% cross-validated accuracy in detecting early-stage Alzheimer's disease in humans (p=3.10E-3).
  • Identified iCAP features enriched for disease-related genes, confirming biological relevance.

Conclusions:

  • The Indicator Cell Assay Platform (iCAP) is a viable tool for blood-based diagnostics.
  • iCAP shows significant potential for early detection of neurodegenerative diseases.
  • The platform's disease-related gene enrichment supports its application in disease research.